Form 4: Arcellx CMO Heery Reports Stock Acquisitions

Arcellx Chief Medical Officer Christopher Heery reported the acquisition of common stock through the vesting of restricted stock units and an employee stock purchase plan.

Summary

• Christopher Heery, Chief Medical Officer of Arcellx, Inc., reported transactions involving the acquisition of common stock.
• On January 2, 2026, Heery acquired 13,021 shares of common stock through the vesting of Restricted Stock Units (RSUs).
• On January 3, 2026, Heery acquired 16,520 shares of common stock through the vesting of RSUs.
• On January 6, 2026, Heery acquired 13,064 shares of common stock through the vesting of RSUs.
• Following these transactions, Heery directly beneficially owns 43,199 shares of Arcellx common stock.
• The reported common stock ownership also includes 284 shares acquired on May 14, 2025, and 310 shares acquired on November 14, 2024, under the Issuer's 2022 Employee Stock Purchase Plan.
• Derivative securities transactions included the grant of 67,708 RSUs on January 2, 2026, vesting over four years, and the vesting of previously granted RSUs on the transaction dates.

Sentiment

Score: 6

Explanation: The filing reports routine insider transactions related to executive compensation (RSU vesting and ESPP acquisitions), which are generally neutral but indicate continued executive ownership and alignment with the company.

Positives

• Chief Medical Officer Christopher Heery increased his direct beneficial ownership of Arcellx common stock to 43,199 shares through the vesting of restricted stock units and participation in the Employee Stock Purchase Plan, aligning executive interests with shareholder value.

Future Outlook

This filing does not contain forward-looking statements or guidance, as it is a report of past insider transactions.

Industry Context

This Form 4 reports routine insider transactions related to executive compensation, which is a standard practice across the biotechnology and pharmaceutical industries to attract, retain, and incentivize key personnel by aligning their interests with long-term shareholder value.

Comparison to Industry Standards

• These transactions represent routine executive compensation through equity awards, which is a standard practice across the biotechnology and pharmaceutical industries to align executive interests with shareholder value. No specific comparable companies or projects are relevant for this type of filing.

Stakeholder Impact

• Shareholders: Increased direct ownership by a key executive, which can be seen as a positive signal of confidence and alignment of interests.
• Employees: Reflects standard executive compensation practices, which are common in the industry for attracting and retaining talent.

Next Steps

• Continued vesting of outstanding Restricted Stock Units as per their respective schedules, contingent on the reporting person remaining a Service Provider.

Key Dates

Recommendation

This Form 4 reports routine insider transactions related to executive compensation, specifically the vesting of restricted stock units and acquisitions through an employee stock purchase plan. These events are expected and do not provide new fundamental information to warrant a change in investment recommendation. The increased direct ownership by the Chief Medical Officer is a neutral to slightly positive signal of alignment but does not alter the investment thesis.

Keywords

Arcellx, ACLX, Form 4, insider transaction, stock acquisition, restricted stock units, RSU, employee stock purchase plan, ESPP, Chief Medical Officer, Christopher Heery